Clinical Trial Update: Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598) [Phase 3]

View source ↗

Summary

Phase 3 trial of pembrolizumab with ipilimumab or placebo in untreated metastatic non-small cell lung cancer has completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: COMPLETED | Results posted: 2021-09-10